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Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and a major preventable cause of stroke and
hospitalization. Its prevalence is on the rise worldwide and experts believe it will continue to rise for the foreseeable
future, due to the ageing population and increased survival from conditions associated with AF. Despite the fact that
oral anticoagulation is effective in preventing strokes due to AF, there is extensive evidence suggesting this therapy
remains underused. Barriers to the prescription of anticoagulation include patients’ age per se, comorbidities,
inadequate risk stratification, perceived risk of falls and bleeding, and the difficulty in achieving a stable international
normalized ratio (INR) on warfarin. Also, asymptomatic patients with AF may not be identified and therefore not be
candidates for anticoagulation. Physicians need continued better education on the identification of patients at risk of
stroke and management of oral anticoagulation. This article reviews the barriers to anticoagulation in patients with AF
in the United Kingdom and considers how those barriers may be overcome.
 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
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INR international normalized ratio
LA left atrial
RCPE Royal College of Physicians of
Edinburgh
RE-LY trial Randomized Evaluation of Long Term
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TTR time in therapeutic range
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Prevention in Octogenarians with
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Atrial fibrillation (AF) is the most common sus-tained cardiac arrhythmia [1] and a major
preventable cause of stroke [2] and hospitalization
[3–5]. Approximately 1 in 100 of the general popu-
lation are thought to have AF, although the prev-
alence exceeds 1 in 10 in elderly cohorts [6,7]. Its
prevalence is on the rise worldwide and experts
believe it will continue to rise for the foreseeable
future, due to the aging population and increased
survival from conditions associated with AF.
Stroke and peripheral thromboembolism are
major complications of AF [8]. This arrhythmia
confers, on average, a fivefold risk of stroke, and
is responsible for one fifth of all strokes. This risk
increases with age. Strokes caused by AF tend to
be more frequently fatal, disabling and recurring
when compared to other causes of stroke. Further-
more, it is noteworthy that paroxysmal AF carries
the same stroke risk as persistent or permanent
forms of the arrhythmia [9], irrespective of symp-
tomatic status. Close to 20% of patients with AF
are asymptomatic [10] and, in some of these
patients, AF is first diagnosed at the time of a
stroke.
Despite the fact that oral anticoagulation is
effective in preventing strokes due to AF, there
is extensive evidence suggesting that this therapy
remains underused [7,11-14]. In fact, although cur-
rent guidelines clearly define indications for anti-
coagulation treatment and its vast impact in the
prevention of stroke, barriers to the implementa-
tion of oral anticoagulation continue to exist
among physicians and patients.
This article reviews the barriers to anticoagula-
tion in patients with AF in the United Kingdom
(UK), as well as potential strategies to overcome
these barriers.Epidemiology of atrial fibrillation in the UK
and the rest of the world: an increasing public
health challenge?
Based on a 1998 survey of 211 general practices
representing a total population of 1.4 million
patients in England and Wales, 1.28% of the total
population of the UK has AF [7,15]. A more recent
study in England revealed that the overall preva-
lence of AF among practices uploading data from
2009 to 2012 was 1.76% [16]. The prevalence of
AF roughly doubles with each advancing decade
of age, from 0.5% at age 50–59 years to almost
9% at age 80–90 years [17]. The incidence of AF
in a cohort of 15,406 adults aged 45–64 years living
in the west of Scotland and screened between1972–1976 and 1977–1979 [18] was 0.54 cases per
1000 person years (or 0.05%) and, during a 20-year
follow-up, 3.5% of this cohort was admitted/dis-
charged from hospital with a diagnosis of AF.
The rate of incident hospitalization for AF was
1.9 cases/1000 person-years. Incidence of AF in
the UK is estimated at up to 0.3% [7,15–19].
There were approximately 8.8 million adults
with AF in the European Union in 2010 and this
number will more than double by the year 2060
[19]. In 2010, the number of adults aged
P55 years with AF could reflect 1.8% of the total
population, and this number will rise to 3.5% by
2060. This increase will be particularly dramatic
for adults over age 75 (from 5.6 million in 2010
to 13.8 million in 2060) [20] (Fig. 1). Several stud-
ies have also projected a doubling of the number
of adults with AF in the United States by the year
2050 [21,22]. A systematic review of the published
literature on the epidemiology of AF in regions of
the world outside North America and Europe
reported prevalence of AF varying among
countries, with different ranges in community
and hospital-based studies, 0.1–4% and 2.8–14%,
respectively [23].
When analyzing these data, we should take into
consideration that the population of the world
amounts to seven billion and more than one third
live in China and India, where reliable epidemio-
logical data on AF are scarce.
In conclusion, despite a lack of data regarding
the epidemiology of AF in non-developed
countries, there is enough evidence suggesting
AF is an increasingly major public health issue
worldwide.
Figure 1. Individuals with atrial fibrillation in the European Union [Ref. [19]], original figure, with permission].
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UK and the world: what is the cost of this
emerging epidemic?
Atrial fibrillation frequently leads to hospitaliza-
tion and is a cause of costly cardiovascular
morbidity including heart failure and stroke.
Almost 20% of all strokes are caused by AF. The
number of AF related hospitalizations is increas-
ing in both the developed and non-developed
world and most patients with AF require long
term pharmacological treatment to decrease the
risk of complications. Consequently, AF imposes
a substantial and growing economic burden on
health care systems.
A previous study has shown that the direct cost
of AF to the UK’s National Health Service (NHS)
was between £244 and £531 million in 1995,
0.6–1.2% of overall health care expenditure in the
UK, but the amount doubled until the year 2000
(AF accounted for 0.9–2.4% of NHS expenditure
in 2000) [24]. These are very conservative esti-
mates since additional costs such as those related
to stroke rehabilitation and warfarin or aspirin-
related hemorrhage were not considered. Further-
more, as they included hospitalizations where AF
was the primary diagnosis, admissions due to
heart failure or stroke caused by AF, where this
condition would be coded in a secondary position,
were not considered. These admissions would cost
an additional £221 million and £228 million,
respectively [24]. The direct cost of AF-related
stroke is up to £24.000 per patient in the UK [25].
The estimated direct and indirect economic bur-
den of all-cause stroke in the USA was US$34.3
billion in 2008 [26], with AF-related stroke theoret-
ically responsible for one fifth of that amount,
probably more given its more disabling nature
compared to other causes of stroke. We shouldalso consider the cost of more recent treatments
for AF, such as catheter ablation. Although some
authors consider catheter ablation a cost-effective
intervention for the treatment of paroxysmal AF
[27,28], the most determining input variables
for a cost-effectiveness assessment of catheter
ablation of AF are the impact on stroke and
hospitalization rates. Some studies have sug-
gested successful catheter ablation for AF may
eventually reduce stroke risk [29–31], but there is
no evidence based on randomized studies that
this therapeutic approach will indeed decrease
thromboembolic risk.
In conclusion, the massive epidemiological and
economic impact of AF is a major concern world-
wide. An effective treatment of conditions associ-
ated with AF, in order to prevent occurrence of
this arrhythmia and its complications, especially
stroke and heart failure, are essential.Use of anticoagulants in the management of
atrial fibrillation in the UK
The Guidance on Risk Assessment and Stroke
Prevention in Atrial Fibrillation (GRASP-AF) tool
searches general practice clinical information to
identify patients with history of AF, reviews their
risk profiles, and provides insights into the preva-
lence and management of AF in England [16].
According to GRASP-AF, the proportion of
patients with AF who were prescribed anticoagu-
lants and antiplatelet agents was 49.3% and
42.5%, respectively, with 6.9% of patients being
prescribed both agents. In total, 57.0% and 83.7%
of the AF population had a CHADS2 score of P2
and P1, respectively. The prescription of both
anticoagulation and antiplatelet agents increased
with increasing CHADS2 score for scores 0–3,
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agulation and 46.5% for antiplatelet drugs at a
score of 6. In total, 34.0% of patients with AF
who had a CHADS2 score P2 were not reported
as having been prescribed an anticoagulant, with
no recording of a contraindication or patient refu-
sal. The uptake of anticoagulant therapy increased
with age for patients aged less than 80 years, but
decreased in patients aged 80 years and over. By
contrast, antiplatelet drug prescription continued
to increase with age in patients aged 80 years
and over. Among high-risk patients with CHADS2
P2, the prescription of anticoagulation was 47.4%
for patients aged 80 years and over compared with
64.5% for younger patients. Overall, this study
suggested that less than half (49.3%) of patients
with a history of AF received an anticoagulant
and that anticoagulant uptake increases through
CHADS2 score 0–3 and thereafter reaches a pla-
teau [16]. These results are similar to those of
another recent study [12] and represent an
improvement compared to what had previously
been described [32]. Nevertheless, if the treatment
threshold for anticoagulation is a CHADS2 score
P1, this would include 84% of the AF population,
which is significantly higher than the percentage
of patients currently given anticoagulation. Fur-
thermore, their study showed an age-dependent
inequality in the prescription of anticoagulants
and antiplatelet agents, which is also a concern
considering elderly patients are at the highest risk
of stroke. The NICE guidelines suggest that 17.400
strokes could be avoided annually by following
their proposed treatment program when com-
pared with no treatment. With the current level
of treatment preventing around 10,300 strokes,
they proposed that a higher level of treatment in
accordance with their recommendations could
result in an additional 7100 strokes being pre-
vented per year.
A few studies have addressed the use of anti-
thrombotic therapy in patients with AF outside
Europe and North America. The use of warfarin
was very low in China (reported at 0.5% and
2.7% in two separate studies) [33,34], but high in
Japan (70.1%) [35]. Aspirin was employed as anti-
thrombotic therapy in at least one third of the
patients and a variable percentage was not receiv-
ing any kind of antithrombotic treatment. Older
patient age was associated with lower prescription
of oral anticoagulants [36].
In conclusion, although the rate of prescription
of anticoagulants in the UK for patients with AF
at moderate to high risk of stroke has been
increasing gradually and is higher than in otherregions of the globe, there is still a significant mar-
gin for improvement.Barriers to anticoagulation
A recent meta-analysis of quantitative studies
revealed that less than 70% of high-risk patients
receive adequate oral anticoagulation therapy
[37]. Potential barriers to appropriate treatment
include inadequate risk stratification, the
(advanced) age of the patient, perceived bleeding
risk and risk of falling, the pitfalls of warfarin,
such as the requirements for regular monitoring,
frequent dosage adjustments, dietary restrictions
and susceptibility to drug interactions, the high
cost of the new oral anticoagulants, the difficulty
in identifying asymptomatic AF patients, and the
lack of appropriate education. Based on a number
needed to treat from the Birmingham Atrial Fibril-
lation Treatment of the Aged (BAFTA) study of 50
to prevent one thromboembolic event or intracra-
nial haemorrhage [38], and on observations from
the study by Cowen et al. [16], it is estimated that
24 in excess of 3000 strokes could potentially be
prevented annually if these individuals were com-
menced on anticoagulation in preference to anti-
platelet drugs [16].
Atrial fibrillation and stroke: which patients to
treat?
Risk stratification is currently based on clinical
risk scores: either the CHADS2 or the CHA2DS2-
VASc score are recommended [8]. These algo-
rithms are based on the presence (or absence) of
risk factors for stroke and thromboembolism,
including congestive heart failure, hypertension,
age, diabetes mellitus, history of stroke, evidence
of atherosclerotic disease and gender. CHADS2
represents a very simple and easy to remember
means of assessing stroke risk. However, it has
been shown to be less reliable in the identification
of low risk patients (those with a score of zero),
who may not be truly low risk (1.9%/year risk of
thromboembolic events) [39]. On the other hand,
CHA2DS2-VASc is able to identify a truly low risk
cohort of patients as a score of zero may associate
with an annual stroke risk of 0% [40]. However,
this algorithm is usually over inclusive, which is
a concern given that some of the subjects who
are given oral anticoagulation based on this score
would never experience an event if they remained
untreated but will have an increased risk of fatal
bleeding whilst being on anticoagulation. Despite
ease of use, these risk scores have shown a limited
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ATRIAL FIBRILLATION IN THE UKcapability in the prediction of stroke, with low
areas under the curve [40,41]. Moreover, they
share some risk factors with scores developed to
estimate hemorrhagic risk (age, history of hyper-
tension and stroke) [42], which adds further com-
plexity to decision making.
Multiple studies have tried to find practical
ways of improving stroke prediction. A biomarker
sub-study of the Randomized Evaluation of Long
Term Anticoagulant Therapy (RE-LY) trial showed
that elevations of troponin I and NT-proBNP are
common in patients with AF and independently
related to increased risks of stroke and mortality
[43]. These parameters added prognostic power
to CHADS2 and CHA2DS2-VASc. In fact, a group
of patients with a CHADS2 score of 0–1 and ele-
vated biomarkers had a higher annual rate of a
composite of thromboembolic events than those
with higher CHADS2 scores and undetectable bio-
markers, and some patients with higher CHADS2
scores and undetectable Troponin I levels could
also be correctly reclassified as low risk [43]. C-
reactive protein and Troponin I have also been
shown to associate with left atrium appendage
thrombus and dense spontaneous echocardio-
graphic contrast [44,45], and preliminary data
from the RE-LY trial suggested a relationship
between D-dimers [46] and interleukin-6 [47],
and clinical events. In addition, recent evidence
suggests renal dysfunction is an important risk
factor for stroke in AF patients, irrespective of
the CHADS2 or CHA2DS2-VASc scores [48,49].
Likewise, several transthoracic echocardio-
graphic parameters have shown promising value
in the prediction of stroke/thromboembolism
[50–54] or surrogate markers of stroke [55–59].
These include left atrial (LA) size measured on
M-mode [50], indexed LA volume [51], left ventric-
ular ejection fraction [57], E/E0 ratio [52] and peak
systolic LA strain rates assessed through speckle-
tracking [54]. The presence of LA appendage
thrombi, dense spontaneous echocardiographic
contrast, LA appendage peak flow velocities
<20 cm/s or complex aortic plaque associates with
increased thromboembolic risk [60,61]. These
abnormalities can be predicted by LA volume, tro-
ponin I values, AF episode duration, history of
stroke or embolism, and C-reactive protein [59].
The roles of echocardiography in thromboembolic
risk assessment in patients with nonvalvular AF
and as a predictor of the incidence and progres-
sion of AF have been thoroughly addressed before
[62,63].
In conclusion, although the traditional CHADS2
or CHA2DS2-VASc scores are a reliable and prac-tical way to estimate thromboembolic risk in
patients with AF, future studies or guidelines
may offer definite recommendations to refine risk
stratification based on the addition of biomarkers
or echocardiographic parameters.Age
Elderly patients with AF are given anticoagula-
tion less often than their younger counterparts
[16]. For CHADS2 scores 1–6, the proportion pre-
scribed an anticoagulant was lower in those aged
80 years and over than in those aged less than
80 years. Conversely, for patients with a CHADS2
score from 1 to 6, the proportion with AF pre-
scribed an antiplatelet agent was higher in those
aged 80 years and over and remained relatively
constant across scores (Fig. 2). This contrasts with
the unequivocal evidence demonstrating that
elderly patients are at a higher risk of all-cause
stroke, including AF-related stroke. Also, the
results of the BAFTA study revealed that warfarin
is superior to aspirin in stroke prevention in the
elderly and does not associate to a significantly
higher risk of severe bleeding [38]. The authors
studied 973 AF patients aged 75 years or over
(mean age 81.5) and concluded that treatment
with warfarin (vs. aspirin) associated to a lower
risk of a composite endpoint of fatal or disabling
stroke (ischemic or hemorrhagic), intracranial
hemorrhage, or clinically significant arterial
embolism (Table 1). The Warfarin versus Aspirin
for Stroke Prevention in Octogenarians with Atrial
Fibrillation (WASPO) trial specifically addressed
the efficacy of adjusted doses of warfarin (INR 2–
3) versus 300 mg of aspirin in octogenarian
patients. The primary endpoint, a composite out-
come of combined death, thromboembolism,
major bleeding and withdrawal from assigned
treatment, was more frequent in the aspirin group
[64]. Although patient age is independently asso-
ciated with the risk of stroke and cardiovascular
events, van Walraven et al. concluded that
anticoagulation remains highly beneficial for
preventing these outcomes in elderly patients
with AF, despite a slight decrease of the relative
risk reduction with oral anticoagulation in older
individuals [65]. Importantly, there was a marked
decrease of stroke risk reduction with antiplatelet
treatment in elderly patients with AF, and no
significant interaction between oral anticoagulants
or antiplatelets and patient’s age regarding seri-
ous hemorrhage or cardiovascular death was seen.
Together, these studies support the hypotheses
that not only is elderly age not a contraindication
Figure 2. Proportion of atrial fibrillation patients prescribed anticoagulation and antiplatelet agents among general practices in England,
according to Cowan C and colleagues, Heart 2013 [Ref. [16]], original figure, with permission].
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Table 1. Results of the BAFTA trial [Ref. [38]].
Warfarin (n = 448) Aspirin (n = 485) Warfarin vs. aspirin
n Risk per year (%) n Risk per year (%) RR (95% CI) p
Stroke 21 1.6 44 3.4 0.46 (0.26–0.79) 0.003
By severity Fatal 13 1.0 21 1.6 0.59 (0.27–1.24) 0.14
Disabling non-fatal 8 0.6 23 1.8 0.33 (0.13–0.77) 0.005
Type of stroke Ischemic 10 0.8 32 2.4 0.30 (0.13–0.63) 0.0004
Hemorrhagic 6 0.5 5 0.4 1.15 (0.29–4.77) 0.83
Unknown 5 0.4 7 0.5 0.69 (0.17–2.51) 0.53
Other intracranial bleeding 2 0.2 1 0.1 1.92 (0.10–113.3) 0.65
Systemic embolism 1 0.1 3 0.2 0.32 (0.01–3.99) 0.36
Total number of events 24 1.8 48 3.8 0.48 (0.28–0.80) 0.0027
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antiplatelet treatment is clearly insufficient to
prevent stroke in this context.Reasons for this risk-treatment paradox in
elderly patients include the high prevalence of
co-morbid factors, impaired cognition with limited
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ATRIAL FIBRILLATION IN THE UKcompliance, use of concomitant medications, the
difficulty in getting stable therapeutic INRs,
frequent falls and the perceived risk of bleeding.R
EFalls and bleeding risk
Elderly patients with AF are frequently not given
anticoagulation therapy on the basis of a high per-
ceived falling and/or bleeding risk. Falls may lead
to major complications in older individuals,
including subdural hematomas, intracerebral
hemorrhage and hip fracture bleeding, which can
be life-threatening. Some authors have suggested
that in AF patients with additional risk factors for
falling, such as sedative use, cognitive impairment,
disability of the lower extremity, gait disturbance
or foot abnormalities, especially those with multi-
ple risk factors, extreme caution in prescribing
anticoagulation should be warranted [66]. One
study analyzed the risk of bleeding from falls in
elderly patients (at least 65 years of age) who are
anticoagulated for AF and concluded that a person
taking warfarin would need to fall about 295 times
in one year for warfarin not to be considered the
optimal therapy [67]. This study had some limita-
tions, including the fact that it studied elderly
patients in community dwelling settings at no par-
ticularly increased risk of falls; it did not consider
other serious bleeding complications beyond sub-
dural bleeding; and it was not a primary evidence
study or meta-analysis. Nevertheless, a study by
Donzé et al. revealed that patients at high risk of
falls who are put on oral anticoagulants do not
have an increased risk of major bleeding. In their
study, only three major bleeds directly related to
a fall were reported in a cohort of 308 patients at
high risk of falling, followed for 12 months [68]. A
systematic review of the use of anticoagulation in
elderly patients with AF at particular high risk of
falls concluded that the benefits of warfarin out-
weigh its risks even in patients who fall, and there-
fore warfarin should be used, rather than aspirin
or no therapy, in elderly patients at risk of falls
[69]. Nevertheless, this general recommendation
should not replace clinical judgment.
Physicians’ most frequent reason for not pre-
scribing warfarin is a perception that patients are
at high risk of bleeding. However, a previous
study suggested that clinicians are no better at
predicting bleeding risk than chance [70]. Bleed-
ing risk perceptions may not correspond to actual
risk of bleeding, and eligible patients may fail to
receive treatment because of faulty judgments.
According to information from trials and registry
data, bleeding events are five to eight times lesslikely than ischemic strokes in AF patients [65].
Several studies have suggested that a perceived
high bleeding risk should not necessarily preclude
the prescription of anticoagulation in patients at
moderate to high risk of stroke. A previous sys-
tematic review concluded that major bleeding
rates for patients receiving antiplatelet therapy
were similar to those receiving anticoagulation,
while the former associated to a higher rate of
ischemic stroke than the latter [71]. These findings
are similar to those of the BAFTA study [63]. A
large multicenter study that enrolled very old
patients concluded that the rate of bleeding is
low (1.87 major hemorrhages per 100 patient-
years; 26 fatal bleeding events, rate of 0.27 per
100 patient-years) [72]. Tincani et al. followed
ninety patients aged 90 years or older with non-
valvular AF and taking anticoagulants, and found
low rates of bleeding and thromboembolism.
Importantly, all the events occurred when the
international normalized ratio (INR) was outside
the target range or after anticoagulation had been
stopped [73]. Therefore, prescribing aspirin rather
than anticoagulation based on a perceived high
bleeding risk is likely to result in poorer outcomes,
as the former is not necessarily safer in regards to
bleeding risk but confers a much lower degree of
protection against stroke.
Conversely, one could argue that bleeding rates
in prospective studies or registries that require
written informed consent for participation and
are less likely to enroll the more acutely ill or frail
patients are not representative of real-life clinical
practice. It is worth remembering that the risk of
both hemorrhage and stroke are highest when
AF is newly diagnosed and during the initiation
of anticoagulation medication, and therefore
clinical trials designed to evaluate the safety and
efficacy of new anticoagulant drugs should
include patients without prior exposure to antico-
agulation. As major bleeding events, especially
intracranial bleeds, may be devastating when
occurring, physicians should be able to accurately
estimate the bleeding risk of their patients. This
task is not straightforward, as many of the known
risk factors for bleeding overlap with stroke risk
factors. Bleeding risk factors include advanced
age, uncontrolled hypertension, history of myo-
cardial infarction or ischemic heart disease, cere-
brovascular disease, anemia or a history of
bleeding, renal dysfunction, and the concomitant
use of other drugs such as antiplatelet agents. To
date, several risk scores have been developed to
estimate bleeding risk in AF patients [17,74–76],
and the use of the HAS-BLED score [17] is
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Despite the limitations of these risk stratification
schemes (wide variation in the proportion of
patients considered to be low, intermediate and
high risk, a lack of common definition of major
bleeding, different lengths of follow-up and mod-
est areas under the curve in the prediction of
bleeding), they offer a starting point for physicians
to consider bleeding when initiating oral anticoag-
ulation and, importantly, to think about correct-
able risk factors, such as hypertension, renal
dysfunction (to a degree), unstable INRs and con-
comitant aspirin or nonsteroidal anti inflamma-
tory drugs.
It should be noted that randomized studies
assessing the efficacy and safety of the new oral
anticoagulants, such as dabigatran [77], rivarox-
aban [78] and apixaban [79], suggested these could
eventually associate to a lower risk of bleeding
compared to warfarin. An indirect comparison
analysis of dabigatran (2 doses), apixaban and riv-
aroxaban for their relative efficacy and safety
against each other did not find profound
differences in efficacy between them, although
dabigatran 150 mg BID was superior to rivarox-
aban for some efficacy endpoints (such as a
composite of stroke and systemic embolism),
whereas major bleeding was significantly lower
with dabigatran 110 mg or apixaban [80]. Future
studies may eventually confirm or refute these
preliminary findings.
In conclusion, although bleeding complications
can be devastating, most patients with a high
CHA2DS2-VASC score benefit from oral anticoag-
ulation even if their bleeding risk is high, given
their much higher absolute risk of stroke com-
pared to hemorrhage. Only in rare patients with
a relatively low stroke risk and a very high risk
of bleeding may the withholding of oral anticoag-
ulation be considered. The HAS-BLED model may
help identify those individuals at highest bleeding
risk where prevention measures should be
applied, including a better blood pressure control,
more regular INR measurements (or eventually
the use of one of the new oral anticoagulants)
and avoidance of antiplatelet drugs.Patients with asymptomatic atrial fibrillation: if
we do not detect it, how can we treat it?
Research has shown that, even in patients with
documented symptomatic AF, asymptomatic
recurrences are common [81]. In fact, asymptom-
atic arrhythmia events occur more frequently than
symptomatic ones in patients with paroxysmal AF,with up to 90% of paroxysmal AF episodes being
asymptomatic [81,82]. Among patients with AF-
related stroke, the cerebrovascular event may be
the first symptom of AF in almost one fourth of
the cases. Although one could speculate that tran-
sient asymptomatic episodes of AF could be less
dangerous than sustained ones, several studies
suggested the annual risk of stroke in those with
paroxysmal AF is similar to that of patients with
permanent AF, and subclinical/asymptomatic
atrial tachyarrhythmias are independently associ-
ated with higher risk of ischemic stroke and sys-
temic embolism [83,84]. In patients with history
of shortness of breath, palpitations, syncope, chest
discomfort or cerebrovascular event, manual
pulse palpation should be performed to deter-
mine the presence of an irregular pulse that could
indicate underlying AF. An electrocardiogram
should then be performed on all patients, regard-
less of symptomatic status, in whom a diagnosis of
AF is suspected based on the detection of an irreg-
ular pulse. Hobbs et al. had ECGs performed in
177 asymptomatic individuals with risk factors
for AF, an irregular pulse and no known history
of AF and concluded that 17.5% were in AF [85].
Insights from the Royal College of Physicians of
Edinburgh (RCPE) UK Consensus Conference on
the management of AF included the need for
appropriate detection and thromboprophylaxis of
AF for the prevention of stroke, with emphasis
on screening for AF in people aged 65 years or
older in the context of a wider national screening
program [86]. Where paroxysmal AF is suspected,
including after ischemic stroke or transient ische-
mic attack, longer ECG monitoring periods (at
least 24 h) or event recorders should be used,
which is pertinent given the high incidence of
asymptomatic AF paroxysms and the fact that AF
can be found in one in 20 patients presenting with
an acute ischemic stroke [86,87]. Different screen-
ing methods include the interrogation of devices
implanted for different reasons, such as pacemak-
ers and defibrillators, or the implantation of loop
recorders when the identification of AF will
potentially have a major clinical impact. A novel
algorithm analyzing signals recorded using an
iPhone 4S accurately distinguished pulse record-
ings during AF from sinus rhythm [88].
In conclusion, physicians should be alerted to
the fact that asymptomatic AF carries a similar risk
of thromboembolic events to symptomatic AF. The
identification of subclinical AF through a compre-
hensive screening program or using ECG moni-
toring systems is of paramount value in the
prevention of AF-related complications.
R
EV
IE
W
 A
RT
IC
LE
J Saudi Heart Assoc
2015;27:31–43
BARRA, FYNN 39
ATRIAL FIBRILLATION IN THE UKPitfalls of warfarin: is it worth the trouble?
Anticoagulation is a life-saving treatment for
many patients with AF. Warfarin has been the
only option for decades, but more recently several
new oral anticoagulants have become available.
Whether these allegedly safer options will have a
major impact in the management of AF still
remains to be determined. However, their prom-
ises of added convenience seem to be well-
founded. Food does not influence their metabo-
lism, drug–drug interactions are uncommon, pre-
dictable anticoagulant effect is achieved with
fixed doses without the need for routine labora-
tory monitoring and, because of their rapid onset
of action, parenteral anticoagulant bridging ther-
apy is not necessary when initiating anticoagula-
tion. The so-called ‘‘pitfalls’’ of warfarin may
partly account for a lower than optimal rate of pre-
scription of anticoagulation in AF patients who
otherwise would be entitled to anticoagulation
treatment. Due to the marked inter-individual
dose response and day-to-day variation in dose
response within individuals, treatment with war-
farin requires dose adjustment with measurement
of the INR. Several studies indicate a clear associ-
ation between a low time in therapeutic range
(TTR) and an increased risk of vascular events
and major hemorrhage in patients on Warfarin
[89–91]. A meta-regression analysis of recently
published studies reported a mean TTR in all
studies of 64% [92], although a wide variation
was seen, occasionally with TTRs as low as 29%.
A marked benefit against stroke and total vascular
events for patients on warfarin treated at centersFigure 3. Cumulative risk of stroke, myocardial infarction, systemic embo
therapeutic range (TTR) below or above 65%, according to Connolly SJ awith mean TTRs above 65% has been docu-
mented; [91] no apparent benefit was found for
patients treated at centers achieving mean TTRs
below 65%. Their findings suggested a threshold
TTR (65%) below which the benefit of warfarin
over clopidogrel plus aspirin is questionable [91]
(Fig. 3). Practices, centers, and regions need to
assess the TTR achieved in their own patients
and to set a minimum target TTR of 60–65%. The
use of warfarin when the TTR is considerably
lower than 65% is probably detrimental. The use
of anticoagulation clinics and computerized deci-
sion support algorithms has been shown to
improve TTR [93,94].
The choice between warfarin and one of the new
oral anticoagulants is not straightforward. Table 2
includes a list of recommendations that may help
in the decision-making process.
In conclusion, treatment with Warfarin should
not be precluded on the basis of its long-known
pitfalls. Instead, one should not forget the
unequivocal impact of anticoagulation in the pre-
vention of AF-related stroke. Setting a minimum
target TTR of at least 65%, eventually with the
use of anticoagulation clinics and computerized
decision support algorithms, or prescribing one
of the new oral anticoagulants in patients with
highly variable/unstable INRs should be strongly
considered.Conclusion
Atrial fibrillation is a major public health issue.
Oral anticoagulants are effective in preventinglism, or vascular death for patients treated at centers with a time in
nd associates, Circulation 2008 [Ref. [91]].
Table 2. General recommendations regarding the choice between warfarin and one of the new oral anticoagulants, according to
European guidelines [95].
U Patients who are stable on warfarin and whose INR values are mostly in the therapeutic range need not be switched
U Patients who are noncompliant with warfarin should not be switched to the new agents because missed doses of these
shorter acting anticoagulants can be more detrimental than missed doses of warfarin
U Patients with valvular AF or mechanical heart valves, with significant hepatic dysfunction or a creatinine clearance below
30 mL/min should receive warfarin
U If one of the new oral anticoagulants is prescribed in patients with moderate renal dysfunction, rivaroxaban or apixaban
seem better choices given their lower degree of renal excretion when compared to dabigatran
U As gastrointestinal bleeding seems more common with dabigatran and rivaroxaban than with warfarin, patients with a
recent history of gastrointestinal bleeding and a moderate to high risk of AF-related stroke should be given apixaban or
warfarin. If the latter is prescribed, more frequent INR measurements (every two weeks) should be recommended
U Dyspepsia occurs in up to 10% of patients on dabigatran, so patients with upper gastrointestinal complaints (other than
bleeding) may do better on apixaban, rivaroxaban or warfarin
U In patients who have suffered an ischemic stroke on warfarin, dabigatran 150 mg twice daily may be considered
U Patients at lower risk for stroke but nonetheless with indication for oral anticoagulation are better suited for dabigatran or
apixaban, as such patients were not included in the ROCKET-AF trial
UWhen one expects the potential need to reverse the anticoagulant effect, such as in patients scheduled for AF ablation, the
lack of a specific antidote for any of the new oral anticoagulants may be of concern for some operators
Legends: AF, atrial fibrillation; ROCKET-AF trial, Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation trial.
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extensive evidence suggests this therapy remains
underused. Patients’ age per se, their comorbidity
burden, the perceived risk of falls and bleeding,
the difficulty in achieving stable INR control and
high time in therapeutic range, a sub-optimal
identification of asymptomatic patients with atrial
fibrillation, and occasionally insufficient education
regarding the benefit of anticoagulation in these
patients are known barriers to the prescription of
anticoagulation, and eligible patients may fail to
receive treatment because of faulty judgments.
Physicians need continuously better education
on the management of oral anticoagulation and
to be aware of the importance of atrial fibrillation
and the devastating consequences of not treating
it adequately.References
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